Cargando…

Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility

BACKGROUND AND PURPOSE: It has been shown that erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun Young, Moon, Chanil, Kim, Kyung Suk, Oh, Ki Wook, Oh, Seong-il, Kim, Juhan, Kim, Seung Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198716/
https://www.ncbi.nlm.nih.gov/pubmed/25324884
http://dx.doi.org/10.3988/jcn.2014.10.4.342
_version_ 1782339771070152704
author Kim, Hyun Young
Moon, Chanil
Kim, Kyung Suk
Oh, Ki Wook
Oh, Seong-il
Kim, Juhan
Kim, Seung Hyun
author_facet Kim, Hyun Young
Moon, Chanil
Kim, Kyung Suk
Oh, Ki Wook
Oh, Seong-il
Kim, Juhan
Kim, Seung Hyun
author_sort Kim, Hyun Young
collection PubMed
description BACKGROUND AND PURPOSE: It has been shown that erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients. METHODS: Two consecutive studies were conducted. We first recruited 26 subjects for an initial single-arm safety study. After a lead-in period of 3 months to assess the disease progression, rhEPO was infused intravenously (35,000 IU) once per month for 3 months, and the subjects were followed for an additional 3 months. The ALS Functional Rating Scale-Revised (ALSFRS-R) was used for clinical assessment. After confirming the safety of rhEPO, 60 subjects were recruited for the second controlled study (rhEPO and control groups), which involved a total of 6 infusions at a rate of 1/month. RESULTS: There were no serious adverse events in the first study. The mean rate of decline in the ALSFRS-R score was lower during the treatment period than during the lead-in period (mean±SD: 2.6±1.8 and 3.7±2.6, respectively; p=0.02). However, the rate of decline during the subsequent 3 months returned to that observed in the lead-in period. In the second study, the mean rate of decline in ALSFRS-R score was significantly lower in the rhEPO group than in the control group (during months 0-3, 1.8±1.7 vs. 3.1±2.3, p=0.03; during months 4-6, 2.1±2.2 vs. 3.5±2.3, p=0.02). CONCLUSIONS: Intravenous high-dose rhEPO is both safe and feasible for the treatment of ALS. Further investigation using different intervals and doses should be considered.
format Online
Article
Text
id pubmed-4198716
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-41987162014-10-16 Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility Kim, Hyun Young Moon, Chanil Kim, Kyung Suk Oh, Ki Wook Oh, Seong-il Kim, Juhan Kim, Seung Hyun J Clin Neurol Original Article BACKGROUND AND PURPOSE: It has been shown that erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients. METHODS: Two consecutive studies were conducted. We first recruited 26 subjects for an initial single-arm safety study. After a lead-in period of 3 months to assess the disease progression, rhEPO was infused intravenously (35,000 IU) once per month for 3 months, and the subjects were followed for an additional 3 months. The ALS Functional Rating Scale-Revised (ALSFRS-R) was used for clinical assessment. After confirming the safety of rhEPO, 60 subjects were recruited for the second controlled study (rhEPO and control groups), which involved a total of 6 infusions at a rate of 1/month. RESULTS: There were no serious adverse events in the first study. The mean rate of decline in the ALSFRS-R score was lower during the treatment period than during the lead-in period (mean±SD: 2.6±1.8 and 3.7±2.6, respectively; p=0.02). However, the rate of decline during the subsequent 3 months returned to that observed in the lead-in period. In the second study, the mean rate of decline in ALSFRS-R score was significantly lower in the rhEPO group than in the control group (during months 0-3, 1.8±1.7 vs. 3.1±2.3, p=0.03; during months 4-6, 2.1±2.2 vs. 3.5±2.3, p=0.02). CONCLUSIONS: Intravenous high-dose rhEPO is both safe and feasible for the treatment of ALS. Further investigation using different intervals and doses should be considered. Korean Neurological Association 2014-10 2014-10-06 /pmc/articles/PMC4198716/ /pubmed/25324884 http://dx.doi.org/10.3988/jcn.2014.10.4.342 Text en Copyright © 2014 Korean Neurological Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Hyun Young
Moon, Chanil
Kim, Kyung Suk
Oh, Ki Wook
Oh, Seong-il
Kim, Juhan
Kim, Seung Hyun
Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility
title Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility
title_full Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility
title_fullStr Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility
title_full_unstemmed Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility
title_short Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis: A Pilot Study of Safety and Feasibility
title_sort recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198716/
https://www.ncbi.nlm.nih.gov/pubmed/25324884
http://dx.doi.org/10.3988/jcn.2014.10.4.342
work_keys_str_mv AT kimhyunyoung recombinanthumanerythropoietininamyotrophiclateralsclerosisapilotstudyofsafetyandfeasibility
AT moonchanil recombinanthumanerythropoietininamyotrophiclateralsclerosisapilotstudyofsafetyandfeasibility
AT kimkyungsuk recombinanthumanerythropoietininamyotrophiclateralsclerosisapilotstudyofsafetyandfeasibility
AT ohkiwook recombinanthumanerythropoietininamyotrophiclateralsclerosisapilotstudyofsafetyandfeasibility
AT ohseongil recombinanthumanerythropoietininamyotrophiclateralsclerosisapilotstudyofsafetyandfeasibility
AT kimjuhan recombinanthumanerythropoietininamyotrophiclateralsclerosisapilotstudyofsafetyandfeasibility
AT kimseunghyun recombinanthumanerythropoietininamyotrophiclateralsclerosisapilotstudyofsafetyandfeasibility